{"page":{"totalFilteredElements":381},"studies":[{"active":true,"description":"
Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML)


","eudractNumber":null,"id":6082,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"}],"mutations":[{"name":"ABL","id":"mt_203"},{"name":"bcr-abl","id":"mt_57"}],"nctNumber":null,"phase":null,"recruitmentStart":"2016-01-01T14:35:44+01:00","shortTitle":"CML-paed II Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"

NCT-COMPASS:\ndeCOMPressing stomA und zweistufige elektive Resektion vs. Notfall-Resektion\nbei Patienten mit linksseitigem obstruktivem Dickdarmkrebs

DRKS00031827


","eudractNumber":null,"id":9179,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-01-31T10:54:20+01:00","shortTitle":"COMPASS","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Ivosidenib in combination with Azacitidine as first-line treatment for adult patients with newly diagnosed AML with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy: A prospective, longitudinal, multicenter, observational study in Germany.","eudractNumber":null,"id":10267,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT06181734","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-09-13T09:23:35+02:00","shortTitle":"CONFIDHENCE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"COSS Register [COSSIRP]
= Klinisches Register für Kinder, Jugendliche \nund Erwachsene mit Osteosarkomen und Knochentumoren. Das COSS-Register \nbeinhaltet keine Vorgaben an Diagnostik oder Therapie. [s. Homepage der Cooperative OsteoSarkom Studiengruppe, COSS]
","eudractNumber":null,"id":948,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2005-10-01T13:19:16+02:00","shortTitle":"COSS Register - COSSIRP","therapeutical":true,"therapyLines":[]},{"active":true,"description":"International CPT-SIOP-Registry
","eudractNumber":null,"id":1225,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2010-03-01T12:26:23+01:00","shortTitle":"CPT-SIOP Register","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Klinische Plattform zur Erforschung molekularer Veränderung und der Behandlung von Nicht-Kleinzelligem Lungenkrebs","eudractNumber":null,"id":3383,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02622581","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2015-08-16T08:23:05+02:00","shortTitle":"CRISP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumors

EUPAS1000000752
","eudractNumber":null,"id":11546,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-12-16T10:18:52+01:00","shortTitle":"CaboLife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective non-interventional study on effectiveness and safety of Cabozantinib in real-life setting for previously treated patients with neuroendocrine tumors

EUPAS1000000752
","eudractNumber":null,"id":11840,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":null,"shortTitle":"CaboLife","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)","eudractNumber":null,"id":4328,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"uro2","name":"Tumoren der ableitenden Harnwege (Nierenbecken, Ureter, Harnblase, Harnröhre)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT03374267 ","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2017-11-30T09:34:51+01:00","shortTitle":"Carat","therapeutical":false,"therapyLines":[]},{"active":true,"description":"

A phase 2b, randomized, blinded,\nplacebo-controlled trial investigating the efficacy and safety of visugromab\nversus placebo, both in combination with pembrolizumab, pemetrexed, and\ncis-/carboplatin, in participants with newly diagnosed metastatic non-squamous\nnon-small cell lung cancer (GDFATHER-LUNG-01)

","eudractNumber":"2024-516792-32","id":10166,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07098988","phase":{"id":"ph_16","name":"IIB"},"recruitmentStart":"2026-01-14T09:32:05+01:00","shortTitle":"Catalym CTL-002-003 GDFATHER-LUNG-01","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}